tradingkey.logo

GlucoTrack Inc

GCTK

6.100USD

-0.130-2.09%
Horarios del mercado ETCotizaciones retrasadas 15 min
2.60MCap. mercado
PérdidaP/E TTM

GlucoTrack Inc

6.100

-0.130-2.09%
Más Datos de GlucoTrack Inc Compañía
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Información de la empresa
Símbolo de cotizaciónGCTK
Nombre de la empresaGlucoTrack Inc
Fecha de salida a bolsaApr 09, 2013
Director ejecutivoMr. Paul V. Goode, Ph.D.
Número de empleados11
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 09
Dirección301 Rt 17 North
CiudadRUTHERFORD
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal07070
Teléfono197286757878
Sitio Web
Símbolo de cotizaciónGCTK
Fecha de salida a bolsaApr 09, 2013
Director ejecutivoMr. Paul V. Goode, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark Tapsak, Ph.D.
Mr. Mark Tapsak, Ph.D.
Vice President of Technology
Vice President of Technology
91.00
-85.06%
Mr. James P. (Jp) Thrower
Mr. James P. (Jp) Thrower
Vice President - Engineering
Vice President - Engineering
79.00
--
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
75.00
--
Mr. John Ballantyne
Mr. John Ballantyne
Director
Director
69.00
--
Ms. Drinda Benjamin
Ms. Drinda Benjamin
Vice President of Marketing
Vice President of Marketing
40.00
--
Dr. Victoria E. Carrbrendel, Ph.D.
Dr. Victoria E. Carrbrendel, Ph.D.
Director
Director
--
--
Ms. Erin Carter
Ms. Erin Carter
Independent Director
Independent Director
--
--
Mr. Ted Williams
Mr. Ted Williams
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
--
--
Mr. Luis J. Malave
Mr. Luis J. Malave
Independent Director
Independent Director
--
--
Mr. Paul V. Goode, Ph.D.
Mr. Paul V. Goode, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark Tapsak, Ph.D.
Mr. Mark Tapsak, Ph.D.
Vice President of Technology
Vice President of Technology
91.00
-85.06%
Mr. James P. (Jp) Thrower
Mr. James P. (Jp) Thrower
Vice President - Engineering
Vice President - Engineering
79.00
--
Mr. Andrew K. Balo
Mr. Andrew K. Balo
Independent Director
Independent Director
75.00
--
Mr. John Ballantyne
Mr. John Ballantyne
Director
Director
69.00
--
Ms. Drinda Benjamin
Ms. Drinda Benjamin
Vice President of Marketing
Vice President of Marketing
40.00
--
Dr. Victoria E. Carrbrendel, Ph.D.
Dr. Victoria E. Carrbrendel, Ph.D.
Director
Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 17 de jun
Actualizado: mar., 17 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
John A Ballantyne Rev Trust
8.06%
Alerus Financial, N.A.
0.88%
Malave (Luis)
0.42%
Virtu Americas LLC
0.15%
Carter (Erin Catherine)
0.13%
Other
90.35%
Accionistas
Accionistas
Proporción
John A Ballantyne Rev Trust
8.06%
Alerus Financial, N.A.
0.88%
Malave (Luis)
0.42%
Virtu Americas LLC
0.15%
Carter (Erin Catherine)
0.13%
Other
90.35%
Tipos de accionistas
Accionistas
Proporción
Corporation
8.14%
Bank and Trust
0.88%
Individual Investor
0.66%
Research Firm
0.15%
Investment Advisor
0.10%
Investment Advisor/Hedge Fund
0.10%
Venture Capital
0.04%
Other
89.94%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
33
57.11K
10.06%
+7.02K
2025Q1
39
2.63M
26.00%
+2.61M
2024Q4
34
288.83K
2.77%
+184.21K
2024Q3
32
114.00K
32.14%
+19.53K
2024Q2
25
96.30K
35.98%
+32.90K
2024Q1
25
100.82K
37.68%
+41.48K
2023Q4
20
58.71K
36.83%
-16.43K
2023Q3
19
75.13K
44.69%
+1.11K
2023Q2
16
74.00K
44.15%
+21.12K
2023Q1
13
53.02K
34.20%
+204.00
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
John A Ballantyne Rev Trust
45.73K
8.06%
--
--
Apr 21, 2025
Alerus Financial, N.A.
5.00K
0.88%
+4.99K
+41566.67%
Mar 31, 2025
Malave (Luis)
2.39K
0.42%
--
--
Apr 21, 2025
Virtu Americas LLC
853.00
0.15%
+853.00
--
Mar 31, 2025
Carter (Erin Catherine)
761.00
0.13%
--
--
Apr 21, 2025
HRT Financial LP
587.00
0.1%
+587.00
--
Mar 31, 2025
Sabby Management, LLC
539.00
0.1%
+539.00
--
Dec 31, 2024
Alma Diversified Holdings LLC
429.00
0.08%
--
--
Sep 05, 2024
Goode Paul
358.00
0.06%
+42.00
+13.29%
Apr 21, 2025
XTX Markets LLC
231.00
0.04%
+160.00
+225.35%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jan 30, 2025
Merger
20<1
Jan 30, 2025
Merger
20<1
Jan 30, 2025
Merger
20<1
Jan 30, 2025
Merger
20<1
May 15, 2024
Merger
5<1
May 15, 2024
Merger
5<1
Fecha
Tipo
Relación
Jan 30, 2025
Merger
20<1
Jan 30, 2025
Merger
20<1
Jan 30, 2025
Merger
20<1
Jan 30, 2025
Merger
20<1
May 15, 2024
Merger
5<1
May 15, 2024
Merger
5<1
May 15, 2024
Merger
5<1
May 15, 2024
Merger
5<1
KeyAI